Lobbying registration dated 2026-03-30
Registrant: Arima Ventin
Client: AbbVie Corporation
Targeted institutions:
Privy Council Office (PCO)
Employment and Social Development Canada (ESDC)
Intergovernmental Affairs Secretariat (IGA)
Health Canada (HC)
Indigenous Services Canada (ISC)
National Research Council (NRC)
Canadian Institutes of Health Research (CIHR)
National Defence (DND)
Global Affairs Canada (GAC)
House of Commons
Prime Minister's Office (PMO)
Public Services and Procurement Canada (PSPC)
Atlantic Canada Opportunities Agency (ACOA)
Invest in Canada Hub
Treasury Board Of Canada Secretariat (TBS)
Senate of Canada
Immigration and Refugee Board (IRB)
Royal Canadian Mounted Police (RCMP)
Veterans Affairs Canada (VAC)
Public Health Agency of Canada (PHAC)
Patented Medicine Prices Review Board (PMPRB)
Correctional Service of Canada (CSC)
Finance Canada (FIN)
Innovation, Science and Economic Development Canada (ISED)
Acts: Patent Act
Government funding received:
Lobbying activity details:
Communications regarding intellectual property protection of prescription drugs, including the Patent Act, the Patented Medicines Regulations, the Patented Medicine Notice of Compliance (PMNOC) Regulations, the Patent Term Adjustment regime and Health Canada’s Data Protection regime.
Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.
Public Health Agency of Canada, regarding the federal response to the hepatitis C virus.
Communications regarding national pharmacare legislation, regulations, policies or programs.
Communications regarding Health Canada's Regulatory Innovation Agenda regarding proposed regulatory amendments and guidelines to enable agile licensing of drugs and medical devices.
Communications with Health Canada regarding guidelines for pediatric action plans.
Communications with Health Canada regarding the evolution of the regulatory framework to address advanced therapeutic products.
Innovation, Science and Economic Development (ISED)'s Health Emergency Readiness program, insofar as it pertains to growth and development of the life sciences industry in Canada.
Communication regarding free trade agreements as they relate to the biopharmaceutical industry.
Federal Government Non Insured Health Benefits program with respect to reimbursement of a prescription medicine and changes in type of reimbursement
Communications with Health Canada regarding the application of its nitrosamine guidelines.
Communications regarding access to and approval of medicines addressing the growing public health threat of antimicrobial resistance.
Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.
Engagement with Health Canada’s Regulatory Operations & Enforcement branch regarding supply chain resilience & integrity; mitigating and alleviating drug shortages.
Communications with Heath Canada regarding modernization of the medical devices regulatory framework.
Communications with Health Canada regarding modernization of clinical trials regulations, including diversity and inclusivity of clinical trials.
The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.
Communications regarding the design and implementation of the federal Drugs for Rare Diseases strategy.
Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape.